NO20062229L - Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er) - Google Patents

Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)

Info

Publication number
NO20062229L
NO20062229L NO20062229A NO20062229A NO20062229L NO 20062229 L NO20062229 L NO 20062229L NO 20062229 A NO20062229 A NO 20062229A NO 20062229 A NO20062229 A NO 20062229A NO 20062229 L NO20062229 L NO 20062229L
Authority
NO
Norway
Prior art keywords
agent
strontium
amino acid
treating cancer
mineral
Prior art date
Application number
NO20062229A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Tallberg
Original Assignee
Helsingfors Institution For Bi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsingfors Institution For Bi filed Critical Helsingfors Institution For Bi
Publication of NO20062229L publication Critical patent/NO20062229L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20062229A 2003-10-17 2006-05-18 Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er) NO20062229L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03103850A EP1523985B1 (de) 2003-10-17 2003-10-17 Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
PCT/FI2004/000618 WO2005037295A1 (en) 2003-10-17 2004-10-15 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)

Publications (1)

Publication Number Publication Date
NO20062229L true NO20062229L (no) 2006-05-18

Family

ID=34354592

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062229A NO20062229L (no) 2003-10-17 2006-05-18 Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)

Country Status (11)

Country Link
US (2) US20070031476A1 (de)
EP (1) EP1523985B1 (de)
CN (1) CN1886143B (de)
AT (1) ATE460168T1 (de)
AU (1) AU2004281559B2 (de)
DE (1) DE60331654D1 (de)
DK (1) DK1523985T3 (de)
ES (1) ES2342461T3 (de)
NO (1) NO20062229L (de)
RU (1) RU2363479C2 (de)
WO (1) WO2005037295A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI122450B (fi) * 2007-12-28 2012-01-31 Neurofood Ab Oy Koostumus steriilin inflammaation hoitoon
RU2440037C2 (ru) * 2009-10-19 2012-01-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ определения направленности патологического процесса при раке легкого
CN103153267B (zh) * 2010-08-18 2015-07-22 高露洁-棕榄公司 口腔护理产品及其使用和制备方法
FI123756B (fi) * 2010-09-21 2013-10-31 Neurofood Ab Oy Parannettu lisäravinne syövän hoitamiseksi tai ennaltaehkäisemiseksi
EP2530068A1 (de) 2011-05-31 2012-12-05 Lacer, S.A. Neue Strontiumsalze, deren Synthese und Verwendung bei der Behandlung von Osteoporose
WO2013013003A1 (en) * 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
KR102282865B1 (ko) * 2014-07-21 2021-07-28 옥소라이프, 에스.엘. 비당뇨병 암컷 포유류에서 불임 치료를 위해, 수정 및 정상 생식을 자극하기 위해, 및 보조 생식 기술의 효과를 개선하기 위해 사용되는 텅스텐(vi) 염

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB602029A (en) * 1942-04-17 1948-05-19 Western Condensing Co Improvements in or relating to process of manufacturing a vitamin concentrate
GB602209A (en) * 1945-06-13 1948-05-21 Norton Co Hydraulic table reciprocating mechanism
EP0366869A3 (de) * 1988-10-17 1991-06-12 Lycon Ag Bakteriostatische,Bakterizide und Pilzabweisende Zusammensetzung und Verwendung derselben
CN1082845A (zh) 1992-12-21 1994-03-02 颜怀玮 营养平衡强化型矿泉水及制造方法
CN1053091C (zh) * 1993-03-13 2000-06-07 彭建汉 天然竹汁保健饮料
CN1048405C (zh) * 1993-04-07 2000-01-19 广西北海市华侨鸿发有限公司 速溶金花茶
CN1113720A (zh) * 1994-05-24 1995-12-27 云南智成科技实业公司 保健液及其生产方法
US5650316A (en) * 1994-06-06 1997-07-22 Research Development Foundation Uses of triplex forming oligonucleotides for the treatment of human diseases
EP0737471A3 (de) * 1995-04-10 2000-12-06 L'oreal Verwendung von Erdalkalimetallsalze als TNF-alpha Inhibitor in einer topischen Zusammensetzung und die so hergestellte Zusammensetzung
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
CN1153053A (zh) * 1995-12-28 1997-07-02 汪贵昌 一种治疗肿瘤的克癌灵中药
US5916143A (en) * 1996-04-30 1999-06-29 Apple; Marc G. Brachytherapy catheter system
WO2000035930A1 (en) * 1998-01-20 2000-06-22 Parker Hughes Institute Vanadium compounds for treating cancer
CA2339473A1 (en) * 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
AU6813700A (en) 1999-08-30 2001-03-26 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
ATE243049T1 (de) * 1999-12-09 2003-07-15 Biosyntech Canada Inc Mineral-polymer hybrid-zusammensetzung
US6456680B1 (en) * 2000-03-29 2002-09-24 Tci Incorporated Method of strontium-89 radioisotope production
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

Also Published As

Publication number Publication date
EP1523985A1 (de) 2005-04-20
CN1886143A (zh) 2006-12-27
RU2363479C2 (ru) 2009-08-10
US20100074968A1 (en) 2010-03-25
AU2004281559B2 (en) 2010-04-01
ES2342461T3 (es) 2010-07-07
ATE460168T1 (de) 2010-03-15
US8703211B2 (en) 2014-04-22
US20070031476A1 (en) 2007-02-08
DE60331654D1 (de) 2010-04-22
DK1523985T3 (da) 2010-05-31
CN1886143B (zh) 2011-04-06
RU2006115785A (ru) 2007-11-27
EP1523985B1 (de) 2010-03-10
AU2004281559A1 (en) 2005-04-28
WO2005037295A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
CY1109422T1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
DE50310516D1 (de) Fredericamycin-derivate
WO2004093803A3 (en) Photochemotherapeutic compounds for use in treatment of pin1-associated states
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200716224A (en) Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
BR0111785A (pt) Composições e métodos para tratamento de candidìase
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
WO2003024996A3 (de) Antibakterielle makrozyklen
DE60137459D1 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
DE602006006915D1 (de) Marrubin und zusammensetzung zur verringerung von schnarchen, verpackung und verfahren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application